Hemostasis Today

February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
Feb 22, 2026, 09:38

Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism

Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared on LinkedIn about the new AHA/ACC guideline by Mark A. Creager et al, adding:

Major Clinical Update: The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism

For my colleagues in Hematology, Internal Medicine, and Cardiology, the newly released 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guidelines for the Management of Acute Pulmonary Embolism introduce significant shifts that directly impact our daily clinical decision-making and patient protocols.

Here are the top takeaways:

1. A New Era of Risk Stratification (Categories A-E)

Move over, simple ‘massive/submassive.’ The guidelines introduce a precise 5-tier Acute PE Clinical Categories system.

This integrates hemodynamics, biomarkers, and RV imaging to clearly delineate patients safe for outpatient management (Categories A and B) from those requiring hospitalization and potential advanced therapies (Categories C, D, E).

 2. Anticoagulation Shifts (Crucial for Hematology)

  • Oral: Direct Oral Anticoagulants (DOACs) are now unequivocally preferred over VKAs for eligible patients to prevent recurrence and reduce bleeding risk.
  • Parenteral: When initial parenteral therapy is needed, Low-Molecular-Weight Heparin (LMWH) is explicitly recommended over UFH.

3. Special Populations Demand Specific Strategies.

The guidelines provide sharp clarity on complex cases:

  • Antiphospholipid Syndrome (APS): A strict recommendation remains: VKAs only. DOACs should be avoided.
  • Obesity and Cancer: DOACs are now considered reasonable over VKAs for obese patients (BMI >30) and are recommended alongside LMWH for extended cancer-associated thrombosis treatment.

 4. The ‘Long Game’ and CTEPD Screening

The job isn’t done at discharge.

Extended anticoagulation is recommended for unprovoked first PE.

Crucially, we must screen for Chronic Thromboembolic Pulmonary Disease (CTEPD) at every clinical visit for at least one year post-PE.

5. Systems of Care
The standard of care is now multidisciplinary.

The implementation of PE Response Teams (PERTs) is highly recommended to ensure timely, risk-stratified interventions for high-risk patients.

Swipe through the slides below for a visual summary of these key updates.

These changes represent a significant move toward more personalized, risk-adapted thrombosis care.”

Title: 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Authors: Mark A. Creager, Geoffrey D. Barnes, Jay Giri, Debabrata Mukherjee, William Schuyler Jones, Allison E. Burnett, Teresa Carman, Ana I. Casanegra, Lana A. Castellucci, Sherrell M. Clark, Mary Cushman, Kerstin de Wit, Jennifer M. Eaves, Margaret C. Fang, Joshua B. Goldberg, Stanislav Henkin, Hillary Johnston-Cox, Sabeeda Kadavath, Daniella Kadian-Dodov, William Brent Keeling, Andrew J. P. Klein, Jun Li, Michael C. McDaniel, Lisa K. Moores, Gregory Piazza, Karen S. Prenger, Steven C. Pugliese, Mona Ranade, Rachel P. Rosovsky, Farla Russo, Eric A. Secemsky, Akhilesh K. Sista, Leben Tefera, Ido Weinberg, Lauren M. Westafer, Michael N. Young

Read the Full Article on Circulation

Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism

Stay updated on all scientific advances with Hemostasis Today.